Zacks Research Analysts Lower Earnings Estimates for BDX

Becton, Dickinson and Company (NYSE:BDX) – Investment analysts at Zacks Research decreased their Q2 2025 earnings per share (EPS) estimates for Becton, Dickinson and Company in a report issued on Wednesday, February 26th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will earn $3.28 per share for the quarter, down from their prior forecast of $3.45. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q3 2025 earnings at $3.58 EPS, Q4 2025 earnings at $4.14 EPS, Q1 2026 earnings at $3.21 EPS, Q2 2026 earnings at $3.79 EPS, Q3 2026 earnings at $4.06 EPS and Q1 2027 earnings at $3.46 EPS.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%.

A number of other research analysts have also recently weighed in on the stock. Piper Sandler lifted their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Barclays raised their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average price target of $278.29.

Becton, Dickinson and Company Stock Performance

BDX opened at $224.44 on Friday. The firm has a fifty day moving average price of $233.13 and a 200 day moving average price of $233.11. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The stock has a market cap of $64.44 billion, a P/E ratio of 37.28, a P/E/G ratio of 1.63 and a beta of 0.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock buyback program on Tuesday, January 28th that allows the company to buyback 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.85%. Becton, Dickinson and Company’s payout ratio is 69.10%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Shana Carol Neal sold 788 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at $3,807,235. This trade represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roland Goette sold 638 shares of Becton, Dickinson and Company stock in a transaction on Monday, December 9th. The shares were sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the sale, the executive vice president now owns 14,217 shares in the company, valued at $3,113,949.51. This represents a 4.29 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,544 shares of company stock valued at $2,370,309. Insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Tompkins Financial Corp boosted its position in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 46 shares during the period. Radnor Capital Management LLC grew its stake in shares of Becton, Dickinson and Company by 1.7% in the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 48 shares in the last quarter. Wesbanco Bank Inc. raised its holdings in shares of Becton, Dickinson and Company by 1.9% in the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock valued at $580,000 after buying an additional 48 shares during the period. Umpqua Bank boosted its holdings in Becton, Dickinson and Company by 1.8% during the 3rd quarter. Umpqua Bank now owns 2,738 shares of the medical instruments supplier’s stock valued at $660,000 after acquiring an additional 49 shares during the period. Finally, Americana Partners LLC grew its position in Becton, Dickinson and Company by 3.5% in the 3rd quarter. Americana Partners LLC now owns 1,468 shares of the medical instruments supplier’s stock valued at $354,000 after acquiring an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.